Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
Diabetes, Obesity and Metabolism · 2025-05 · 27 (5) · 2720-2729
DOI: 10.1111/dom.16275 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 25.02.2025. Verfasst von Michelle Look und 7 weiteren Autor:innen. Beteiligte Einrichtung: San Diego Sports Medicine and Family Health Center, San Diego, California, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Body Composition, Obesity, Overweight. Die Arbeit wurde bisher 202-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Aims
We assessed changes in body composition following tirzepatide treatment in a substudy of participants with obesity or overweight from the SURMOUNT‐1 trial, overall and post hoc in clinically relevant subgroups. Materials and Methods Substudy participants ( n = 160 of the 2539 in SURMOUNT‐1) underwent dual‐energy X‐ray absorptiometry (DXA) at baseline and Week 72. Body composition parameters were evaluated by analysis of covariance, logistic regression or Fisher's exact test. Post hoc subgroup analyses were conducted by sex (female or male), age (25.9 kg).
Results
The 160 participants (pooled tirzepatide doses n = 124, placebo n = 36) with baseline and end of study DXA data were 73% female and had a mean weight of 102.5 kg and body mass index of 38.0 kg/m 2 . The change in body weight, fat mass and lean mass from baseline to Week 72 was −21.3%, −33.9% and −10.9% with tirzepatide and −5.3%, −8.2% and −2.6% with placebo, respectively ( p < 0.001 for all comparisons). Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo. These proportions remained consistent across most subgroup analyses.
Conclusions
In participants with obesity or overweight from the SURMOUNT‐1 trial, tirzepatide treatment significantly reduced body weight, fat mass and lean mass compared with placebo, while in post hoc analyses, the proportion of body weight lost as fat or lean mass was relatively consistent including in clinically relevant subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- San Diego Sports Medicine and Family Health Center, San Diego, California, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
ORCID-Profile: Michelle Look, Julia P Dunn, Robert F Kushner, Dachuang Cao, Charles Harris, Theresa Hunter Gibble, Adam Stefanski, Ryan Griffin
Förderung
- Eli Lilly and Company
Zitieren
APA
Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720-2729. https://doi.org/10.1111/dom.16275
Vancouver
Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720-2729. doi:10.1111/dom.16275
BibTeX
@article{Look2025,
author = {Look, Michelle and Dunn, Julia P and Kushner, Robert F and Cao, Dachuang and Harris, Charles and Gibble, Theresa Hunter and Stefanski, Adam and Griffin, Ryan},
title = {Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {5},
pages = {2720--2729},
doi = {10.1111/dom.16275}
}
EUVIMED